Sort   by:  
 Page size 
ProteomicsHDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma
Purpose: The clinical use of MEK inhibitors in uveal melanoma is limited by the rapid acquisition of resistance. The current study has used multi-omics approaches and drug screens to identify the pan-HDAC inhibitor panobinostat as an effective strategy to limit MEK inhibitor resistance. Experimental...
ORGANISM(S): Homo sapiens (Human) 
2020-05-26 | PXD013988 | Pride
Uveal melanoma Hdac Abpp 
ProteomicsExpression Proteomics of BRAF Inhibitor Resistance in Melanoma Cell Lines
To investigate mechanisms of resistance to BRAF inhibitor therapy in melanoma, BRAF mutant cell lines have been chronically exposed to BRAFi to create phenotypes with acquired drug resistance. Expression proteomics is used to examine the differences between naive and drug-resistant cells.
ORGANISM(S): Homo sapiens (Human) 
2016-12-13 | PXD004342 | Pride
Kinase inhibitor Tmt Melanoma Braf Drug resistance 
ProteomicsActivity-Based Protein Profiling of BRAF Inhibitor Resistance in Melanoma Cell Lines
To investigate mechanisms of resistance to BRAF inhibitor therapy in melanoma, BRAF mutant cell lines have been chronically exposed to BRAFi to create phenotypes with acquired drug resistance. Activity-based protein profiling with desthiobiotinylating ATP probes (ActivX, Thermo) is used to examine ...
ORGANISM(S): Homo sapiens (Human) 
2016-12-13 | PXD004343 | Pride
Abpp Kinase inhibitor Melanoma Braf Drug resistance 
ProteomicsComparison of Targeted MS Methods in Activity-Based Protein Profiling 1: DDA
To examine the different mass spectrometry approaches to monitoring kinases after enrichment with desthiobiotinylating probes for activity-based protein profiling (ABPP), two experiments were performed with H1993 lung cancer cells. First, cell lysates were pre-treated with DMSO vehicle, dasatinib, ...
ORGANISM(S): Homo sapiens (Human) 
2017-11-27 | PXD006095 | Pride
Dda Activity-based protein profiling Dia Prm Srm/mrm Lung cancer 
ProteomicsComparison of Targeted MS Methods in Activity-Based Protein Profiling 2: DIA
To examine the different mass spectrometry approaches to monitoring kinases after enrichment with desthiobiotinylating probes for activity-based protein profiling (ABPP), two experiments were performed with H1993 lung cancer cells. First, cell lysates were pre-treated with DMSO vehicle, dasatinib, ...
ORGANISM(S): Homo sapiens (Human) 
2017-11-27 | PXD006096 | Pride
Dda Activity-based protein profiling Dia Prm Srm/mrm Lung cancer 
ProteomicsComparison of Lung Cancer Proteome Profiles 1: Label Free Quantification
The goal of this project is to compare label free quantification, chemical labeling with tandem mass tags, and data independent acquisition discovery proteomics approaches using lung squamous cell carcinomas and adjacent lung tissues.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2017-03-27 | MSV000080685 | MassIVE
ProteomicsIntegrative functional proteomics identifies PARP1 protein complex differences and PARP inhibitor-mediated DDR and AKT-mTOR signaling in ovarian carcinoma: Phosphoproteomics
BRCA1/2-deficient ovarian carcinoma (OC) has been shown to be particularly sensitive to PARP inhibitors (PARPis) and BRCA1/2 mutation status is currently used as a predictive biomarker for PARPi therapy. Despite eliciting major clinical benefit for the majority of patients, a significant proportion ...
ORGANISM(S): Homo sapiens (Human) 
2022-10-21 | PXD029432 | Pride
Ovarian cancer Phosphoproteomics Parp1 Brca 
ProteomicsIgA transcytosis and tumor antigen recognition govern anti-tumor immunity in ovarian cancer
Although most ovarian cancers show prognostically relevant activated T-cell infiltrates, response rates to immune checkpoint inhibitors are very modest4. Memory B-cell and plasma cell infiltrates have been associated with better outcome in ovarian cancer, but the nature and functional relevance of t...
ORGANISM(S): Homo sapiens (Human) 
2020-12-01 | PXD018079 | Pride
Ovarian cancer Prm Immunoglobulin a Transcytosis Lc-ms/ms Immunotherapy 
ProteomicsNon-canonical EphA2 signaling is a driver of tumor-endothelial cell interactions and metastatic dissemination in BRAF inhibitor resistant melanoma
Acquired BRAF/MEK inhibitor resistance in melanoma results in a new transcriptional state associated with increased risk of metastasis. Here, we identified non-canonical EphA2 signaling as a driver of the resistance-associated metastatic state. We used mass spectrometry-based proteomic and phenotypi...
ORGANISM(S): Homo sapiens (Human) 
2020-11-18 | PXD020250 | Pride
Phosphotyrosine. ephrin a2 Melanoma Braf inhibitor Drug resistance 
ProteomicsNon-canonical EphA2 signaling is a driver of tumor-endothelial cell interactions and metastatic dissemination in BRAF inhibitor resistant melanoma: Phosphoproteomics
Acquired BRAF/MEK inhibitor resistance in melanoma results in a new transcriptional state associated with increased risk of metastasis. Here, we identified non-canonical EphA2 signaling as a driver of the resistance-associated metastatic state. We used mass spectrometry-based proteomic and phenotypi...
ORGANISM(S): Homo sapiens (Human) 
2020-11-18 | PXD020241 | Pride
Melanoma Phosphoproteomics. ephrin a2 Braf inhibitor Drug resistance 
Sort   by:  
 Page size